Pfizer Completes Acquisition of Medivation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
UBS Reiterates Buy on Pfizer (PFE) Following a Meeting with Management
September 30, 2016 11:01 AM EDTUBS reiterated a Buy rating and $38.00 price target on Pfizer (NYSE: PFE) following a meeting with management. The main topics included the recent decision not to break up, M&A/BD strategy, expenses/operating leverage and CNS remaining an attractive therapeutic area for research.
A UBS analyst commented, "Without... More
